CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Drugs (New Approvals & NDA)
Original article

Drug Trials Snapshots: ICOTYDE

ICOTYDENeutral
AI Analysis

Summary

ICOTYDE is an IL-23 receptor antagonist indicated for moderate-to-severe plaque psoriasis in adults and pediatric patients age 12 and older who weigh at least 40 kg.

Importance:1/10
Sentiment:
0.00
IL-23 receptor antagonistpsoriasisdrug profile

Read the original article

Published by FDA Drugs (New Approvals & NDA) on August 11, 2026 3:20 PM

Read Original